• In the second quarter of 2026, Intellia Therapeutics reported a net loss of US$106.63 million, with basic loss per share from continuing operations of US$0.80, while its six‑month net loss reached US$202.87 million and basic loss per share was US$1.61, both reflecting reduced losses versus a year earlier.
• The combination of a slightly higher quarterly net loss but improved loss per share, alongside a smaller half‑year net loss, may influence how investors assess Intellia’s progress in managing costs as it advances its gene‑editing pipeline.
• Next, we’ll examine how this reduced six‑month loss, despite ongoing deficits, may reshape Intellia Therapeutics’ investment narrative and risk profile.

Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Intellia Therapeutics Investment Narrative Recap

To own Intellia Therapeutics, you need to believe that its in vivo CRISPR programs, especially lonvo z and nex z, can eventually justify years of heavy investment and current losses. The latest quarter shows a slightly higher net loss but a better loss per share and a smaller six month deficit, which modestly supports the near term catalyst of advancing late stage trials while leaving the key risk of ongoing cash burn and potential dilution squarely in focus.

The recent Phase 3 HAELO results for lonvo z, with an 87% reduction in hereditary angioedema attacks and a rolling BLA already underway, are the most relevant backdrop to these earnings. The reduced six month loss and improved per share metrics sit alongside this regulatory momentum, reinforcing that the near term story still hinges on converting promising lonvo z data into approval and, eventually, commercial scale, even as funding needs remain significant.

Yet behind the progress on lonvo z, the continued high cash burn and past shareholder dilution highlight a funding risk investors should be aware of as…

Intellia Therapeutics' narrative projects $644.6 million revenue and $117.5 million earnings by 2029. This requires 121.3% yearly revenue growth and a $517.5 million earnings increase from -$400.0 million today.

Uncover how Intellia Therapeutics' forecasts yield a $23.94 fair value, a 98% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts once projected revenue near US$6.0 billion and earnings of about US$1.9 billion by 2029, but with the latest losses and the ongoing risk that Intellia may need further capital to fund its programs, you should recognize how sharply opinions can differ and consider how these forecasts might shift as new data and funding decisions emerge.

Explore 3 other fair value estimates on Intellia Therapeutics - why the stock might be a potential multi-bagger!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Intellia Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Intellia Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Intellia Therapeutics' overall financial health at a glance.

No Opportunity In Intellia Therapeutics?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 53 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.